Residual cancer burden after neoadjuvant therapy can accurately predict breast cancer survival

December 13, 2019

SAN ANTONIO -- Researchers from The University of Texas MD Anderson Cancer Center today reported results from a pooled analysis of more than 5,100 breast cancer patients that found residual cancer burden (RCB) continuous index and classification were independently and strongly prognostic for all breast cancer phenotypes.

The study's results were presented by W. Fraser Symmans, M.D., professor of Pathology, during the 2019 San Antonio Breast Cancer Symposium.

"This meta-analysis indicates that continuous RCB index is an accurate and reliable tool to assess patient prognosis," said Symmans. "Furthermore, we found that these results were consistently generalizable and could help determine the most appropriate treatment plans for patients with all breast cancer subtypes."

Pathological complete response (pCR), defined by the exclusion of any residual cancer, is a known strong prognostic indicator that is useful for communication of residual risk and subsequent treatment plans for breast cancer patients. Similarly, smaller studies have indicated that the extent of residual disease after neoadjuvant chemotherapy is associated with risk of the cancer returning in the future.

In this pooled subject-level analysis, Symmans worked with a team of researchers from the I-SPY Clinical Trials Consortium to analyze data from 12 institutes or clinical trials representing more than 5,100 breast cancer patients from six countries. MD Anderson has hosted a freely available website to calculate RCB since 2007. This is widely used as a resource with educational materials and calculator for RCB index and category. RCB is determined by factors including the dimensions of the primary tumor bed area; the percentage of cancer that is invasive versus in situ; the number of involved lymph nodes and size of the largest metastasis. RCB index was classified as: RCB-I (minimal burden), RCB-II (moderate burden) or RCB-III (extensive burden).

Symmans and colleagues evaluated associations between the continuous RCB index and both event-free survival (EFS) and distant recurrence-free survival (DRFS), adjusting for differences between studies. They also evaluated the association between RCB index and prognosis within each HR/HER2 subtype. Kaplan Meier estimates of EFS and DRFS at five and 10 years were calculated for each RCB class within each phenotype.

Results from the analysis indicated RCB index and classification was an accurate and consistent indicator of prognosis for all four breast cancer subtypes. RCB index also was tightly associated with prognosis over long-term follow-up.

"This pooled analysis confirms and expands upon prior findings that RCB index can predict risk of breast cancer recurrence," said Symmans. "This assessment of prognostic risk can be used to accurately determine disease progression and inform treatment choice for breast cancer patients inclusive of all subtypes."


Prognostic differences by RCB class occurred within five years in HR- breast cancer but extended to 10 years in HR+ breast cancer.After five years, RCB-I patients had slightly worse EFS than pCR in HR- breast cancer and HR+/HER2+ breast cancer, but the same EFS as pCR in HR+/HER2- breast cancer. On the other hand, the large numbers of patients in this study made it possible to observe that a precise estimate of future risk could be calibrated from the actual value of RCB index calculated from a person's surgical resection specimen. That finding could facilitate another step forward in precision in the assessment of treatment, communication of residual risk and treatment planning for patients with breast cancer.

The authors note several limitations to the study, including data collection from multiple institutions which may introduce some variation in clinical methods, the handling of specimens and other factors. Some data were collected prospectively and some retrospectively, another variable factor.

Cancer centers do not all routinely collect data on RCB; this analysis indicates that RCB is a potential predictor of recurrence across breast cancer subtypes. "These findings indicate the importance of implementing residual cancer burden screening as a standard tool during cancer treatment. Routinizing RCB can give a more accurate sense of each patient's prognosis, recurrence and best course of treatment while building an even more robust data set to improve understanding of the relationship between RCB index and long-term prognosis," Symmans said.
This research was supported by the Department of Defense, a National Institutes of Health program grant, the Cancer Prevention Research Institute of Texas and the Breast Cancer Research Foundation.

Symmans reports disclosures of a patent for a mathematical formula used in MD Anderson's RCB index, an unpaid scientific advisory role with co-founder equity in Delphi Diagnostics, Inc. and ownership of publicly traded shares in IONIS Pharmaceuticals.

A full list of collaborating researchers is included in the abstract.

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution's sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 50 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report's "Best Hospitals" survey. It has ranked as one of the nation's top two hospitals for cancer care since the survey began in 1990, and has ranked first 15 times in the last 18 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

University of Texas M. D. Anderson Cancer Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to